Parkinson Disease

The increased risk may be due to changes in the brain’s dopamine system caused by dopamine receptor antagonists or neurobiological effects of schizophrenia.

Research has also shown that patients with Parkinson disease who are able to engage in physical activity can potentially improve the motor and non-motor symptoms associated with the disease.

Seven cases of young people with stiffness throughout their body and an inability to speak presented to hospitals in different cities throughout the country, with seemingly no link between them.

New treatment options offer hopes of better clinical outcomes for patients suffering from Parkinson disease and its debilitating daily symptoms.

Officials with the FDA have approved apomorphine hydrochloride sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease.

Individuals with the progressive condition often struggle to control their motor fluctuations.

Pharmacists play an integral role and can improve patients’ quality of life with proper communication, counseling, and monitoring.

Researchers have identified a channel in nerve cells that may serve as a new approach to targeting Parkinson disease.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.